Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06244082 · ClinicalTrials.gov registry record · Phase 2
Ph2 Open-label Study of AOC 1044 in Duchenne Muscular Dystrophy Participants With Mutations Amenable to Exon44 Skipping
A Phase 2 study of Duchenne Muscular Dystrophy and DMD, sponsored by Avidity Biosciences.
- Active
- Registry status
- Phase 2
- Development phase
- 39
- Enrollment target
- 10
- Study locations
NCT06244082 is a Phase 2 study of Duchenne Muscular Dystrophy and DMD that is active but no longer recruiting, run by Avidity Biosciences. The registered enrollment target is 39 participants, below the 412-participant average among 48 other Duchenne Muscular Dystrophy trials with a reported enrollment target (91% lower). The trial reports 10 study locations across 8 states.
The verdict
NCT06244082, a Phase 2 study of Duchenne Muscular Dystrophy and DMD, is active but no longer recruiting, sponsored by Avidity Biosciences.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 39 participants
- Enrollment target
- 10
- Study locations
Study Summary
AOC 1044-CS2 (EXPLORE44-OLE) is an Open-label Study to Evaluate the Long-Term Safety and Tolerability of AOC 1044 Administered Intravenously to DMD Participants with Mutations Amenable to Exon 44 Skipping.
Conditions Studied
Interventions
- DRUG AOC 1044
Study Locations (10)
California
- University of California, San Diego, Rady's Children's Hospital - La Jolla
- UC Davis Medical Center - Sacramento
- Lucille Packard Children's Hospital at Stanford - San Carlos
Arkansas
- Arkansas Children's Hospital - Little Rock
Georgia
- Rare Disease Research - Atlanta - Atlanta
Massachusetts
- University of Massachusetts Medical School - Worcester
Minnesota
- Gillette Children's Specialty Healthcare - Saint Paul
North Carolina
- Rare Disease Research - Hillsborough
Ohio
- Abigail Wexner Research Institute at Nationwide Children's Hospital - Columbus
Texas
- Neurology Rare Disease Center - Denton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2024-01-22 |
| Est. Completion | 2027-07-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06244082
The ClinicalTrials.gov registry entry for NCT06244082 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 412-participant average among 48 other Duchenne Muscular Dystrophy trials with a reported enrollment target (91% lower). The listed sponsor is Avidity Biosciences, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Duchenne Muscular Dystrophy appearing as the primary indexed condition, and to 1 intervention - of which AOC 1044 is the first listed.
NCT06244082 reports 10 study locations spanning 8 distinct geographic areas - top geographies include California, Arkansas, Georgia.
Frequently Asked Questions
What is clinical trial NCT06244082 about?
NCT06244082 is a clinical study titled "Ph2 Open-label Study of AOC 1044 in Duchenne Muscular Dystrophy Participants With Mutations Amenable to Exon44 Skipping". AOC 1044-CS2 (EXPLORE44-OLE) is an Open-label Study to Evaluate the Long-Term Safety and Tolerability of AOC 1044 Administered Intravenously to DMD Participants with Mutations Amenable to Exon 44 Skipping.
What is the current status of trial NCT06244082?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 39 participants. The study started on 2024-01-22. Estimated completion is 2027-07-31.
What conditions does trial NCT06244082 study?
This clinical trial studies the following conditions: Duchenne Muscular Dystrophy, DMD, Exon 44, Duchenne.
What interventions are being tested in trial NCT06244082?
The interventions under investigation include: AOC 1044 (DRUG).
Who is sponsoring clinical trial NCT06244082?
This trial is sponsored by Avidity Biosciences, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06244082 being conducted?
This trial has 10 study locations across Arkansas, California, Georgia, Massachusetts, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Duchenne Muscular Dystrophy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy (DMD)
RECRUITING · Phase 2
-
A Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy (DMD)
RECRUITING · Phase 2
-
Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients
RECRUITING · Phase 2
-
Givinostat in Duchenne's Muscular Dystrophy Long-term Safety and Tolerability Study
RECRUITING · Phase 2
-
NS-089/NCNP-02-201 in Boys With Duchenne Muscular Dystrophy (DMD)
RECRUITING · Phase 2
-
Vasodilator and Exercise Study for DMD (VASO-REx)
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.